Cetrelimab

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameCetrelimab
Drug Alias NameCetrelimab - Janssen Research and DevelopmentJNJ-63723283JNJ-3283
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsHormone-Sensitive Prostate NeoplasmsSolid tumoursUrinary Bladder Neoplasms +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[30] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesJanssen Pharmaceutica SaJohnson & Johnson Enterprise Innovation IncJohnson & Johnson (China) Investment Ltd +[7] 
Inactive CompaniesJanssen Pharmaceutical KkJanssen Scientific Affairs Llc
Active IndicationsHormone-Sensitive Prostate NeoplasmsSolid tumoursUrinary Bladder Neoplasms +[14] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A